Rigel Reports Fourth Quarter and Full Year 2022 Financial Results …

Mar 7, 2023 · Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE ® net product sales of $21.9 million and REZLIDHIA ™ net product sales of $0.9 million; …

$51
OFF

Rigel Reports Fourth Quarter And Full Year 2022 Financial Results …

1 week from now

Mar 7, 2023 · Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE ® net product sales of $21.9 million and REZLIDHIA ™ net product sales of $0.9 million; …

rigel.com

$35
OFF

Rigel Reports Fourth Quarter And Full Year 2023 Financial Results …

1 week from now

Mar 5, 2024 · Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE ® net product sales of $25.7 million and REZLIDHIA ® net product sales of $3.9 million; …

rigel.com

$0.74
OFF

Rigel Pharmaceuticals Inc. Q4 Earnings Summary - Markets Insider

1 week from now

Mar 5, 2024 · (RTTNews) - Below are the earnings highlights for Rigel Pharmaceuticals Inc. (RIGL): Earnings: $0.74 million in Q4 vs. $1.40 million in the same ...

businessinsider.com

$19.24
OFF

EARNINGS SUMMARY: Details Of Rigel Pharmaceuticals Inc. Q4 …

1 week from now

Mar 2, 2021 · Below are the earnings highlights for Rigel Pharmaceuticals Inc. (RIGL): -Earnings: -$19.24 million in Q4 vs. -$17.20 million in the same period last year. -EPS: -$0.

rttnews.com

$0.01
OFF

Rigel Pharmaceuticals (RIGL) Q4 Earnings And Revenues Surpass …

1 week from now

Mar 7, 2023 · Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.07 per share. This compares to loss of …

yahoo.com

$0.11
OFF

EARNINGS SUMMARY: Details Of Rigel Pharmaceuticals Inc. Q4 …

1 week from now

Mar 2, 2021 · -EPS: -$0.11 in Q4 vs. -$0.10 in the same period last year. -Analysts projected -$0.11 per share -Revenue: $1 EARNINGS SUMMARY: Details of Rigel Pharmaceuticals Inc. …

nasdaq.com

$57
OFF

Rigel Pharmaceuticals Reports Preliminary Q4 Results; Issues 2025 …

1 week from now

4 days ago · Rigel Pharmaceuticals, Inc. (RIGL) said it expects to report fourth quarter total revenue of $57.6 million, compared to $35.8 million for the same period of 2023. ... Rigel …

rttnews.com

$57
OFF

Rigel Pharmaceuticals Expects Higher Q4 Revenue, Provides 2025 …

1 week from now

4 days ago · -- Rigel Pharmaceuticals said Monday it expects Q4 total revenue of $57.6 million, up from $35.8 million a year earlier. Analysts polled by FactSet expect $47.4 million. The …

marketscreener.com

$1.40
OFF

Rigel Pharmaceuticals Inc. Q4 Earnings Summary - Markets Insider

1 week from now

Mar 7, 2023 · (RTTNews) - Below are the earnings highlights for Rigel Pharmaceuticals Inc. (RIGL): Earnings: $1.40 million in Q4 vs. -$22.64 million in the same period last year. EPS: …

businessinsider.com

$57
OFF

Rigel Pharmaceuticals Reports Preliminary Q4 Results; Issues 2025 ...

1 week from now

4 days ago · (RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) said it expects to report fourth quarter total revenue of $57.6 million, compared to $35.8 million for the same period of 2023. …

businessinsider.com

$19.24
OFF

EARNINGS SUMMARY: Details Of Rigel Pharmaceuticals Inc. Q4 …

1 week from now

Mar 2, 2021 · (RTTNews) - Below are the earnings highlights for Rigel Pharmaceuticals Inc. (RIGL): -Earnings: -$19.24 million in Q4 vs. -$17.20 million in the ...

businessinsider.com

$57
OFF

Rigel Provides Business Update And 2025 Outlook - Morningstar

1 week from now

4 days ago · While Rigel is still determining final results for the fourth quarter of 2024, the company expects to report fourth quarter total revenue of $57.6 million, compared to $35.8 …

morningstar.com

$57
OFF

Rigel Provides Business Update And 2025 Outlook

1 week from now

4 days ago · While Rigel is still determining final results for the fourth quarter of 2024, the company expects to report fourth quarter total revenue of $57.6 million, compared to $35.8 …

rigel.com

$200
OFF

Rigel Pharmaceuticals Sets 2025 Sales Outlook Above Estimates

1 week from now

Rigel Pharmaceuticals (NASDAQ:RIGL) has set its financial expectations for 2025, projecting total revenue of approximately $200M to $210M ($193.51M estimate), with net product sales of …

msn.com

$57
OFF

Rigel Provides Business Update And 2025 Outlook - PR Newswire

1 week from now

4 days ago · While Rigel is still determining final results for the fourth quarter of 2024, the company expects to report fourth quarter total revenue of $57.6 million, compared to $35.8 …

prnewswire.com

FAQs about Rigel Reports Fourth Quarter and Full Year 2022 Financial Results … Coupon?

What is Rigel Pharmaceuticals' fourth quarter revenue?

(RTTNews) - Rigel Pharmaceuticals, Inc. (RIGL) said it expects to report fourth quarter total revenue of $57.6 million, compared to $35.8 million for the same period of 2023. Rigel expects to report fourth quarter net product sales of $46.5 million, compared to $29.5 million for the same period of 2023. ...

How much revenue does Rigel expect in 2023?

For the full year, Rigel expects to report total revenue of $179.3 million, including net product sales of $144.9 million, compared to total revenue of $116.9 million in 2023, which included net product sales of $104.3 million. ...

Is Rigel Pharmaceuticals (Rigl) a good stock to buy?

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) Q4 2023 Earnings Call Transcript March 5, 2024 Rigel Pharmaceuticals, Inc. isn't one of the 30 most popular stocks among hedge funds at the end of the third quarter ( see the details here ). ...

How did Rigel perform in the fourth quarter of 2022?

For the fourth quarter of 2022, Rigel reported a net income of $1.4 million, or $0.01 per basic and diluted share, compared to a net loss of $22.6 million, or $0.13 per basic and diluted share, for the same period of 2021. ...

How much money will Rigel make in 2025?

Rigel anticipates 2025 total revenue of approximately $200 to $210 million, including: net product sales of approximately $185 million to $192 million. The company anticipates it will report positive net income for 2025. Also, Rigel plans to initiate a Phase 2 clinical study in recurrent glioma in 2025. ...

Who is Rigel Pharmaceuticals?

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a biotechnology company dedicated to discovering, developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. Founded in 1996, Rigel is based in South San Francisco, California. ...